ArticleRheumatology (Oxford, England)2025
Incidence and prevalence of Behçet's disease in Oslo, Norway: a two-decade population-based analysis.
Article in Rheumatology (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- The epidemiology of inflammatory rheumatic diseases in Germany in a European context: a systematic review to support workforce planning.EULAR rheumatology open · 2026Article
- Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo estimate the incidence and prevalence of Behçet's disease (BD) in Oslo, Norway from 1999 to 2021.
methodsFirst, we identified BD cases from the Oslo hospital administrative databases and Norwegian connective tissue and vasculitis registry (NOSVAR) using the code for BD (M35.2) of the 10th revised edition of the International Classification of Diseases. Next, all identified cases were manually chart-reviewed and classified by the International Study Group (ISG) criteria and International Criteria for Behçet's Disease (ICBD). Cases meeting at least one of the two criteria were included.
resultsIn total 58 patients were included, 43 of them incidental; 52% were female and 57% with non-Norwegian ancestry. The mean age at symptom onset was 24 years and at diagnosis 33 years. The median diagnostic delay was 5 (interquartile range 2-12) years. Incidence was 0.29 (95% CI: 0.18, 0.41) per 100 000 person-years, higher in non-Norwegians (0.44 vs 0.22). Among Norwegians, the incidence was higher in females (0.27 vs 0.08). The prevalence was 2.36 per 100 000 inhabitants in 1999 and 7.14 in 2021, higher for non-Norwegians (12.68 vs 4.32 in 2021). Incidence and prevalence appeared to increase, but reclassification by ISG criteria adjusted the trend downward. This trend was significantly reduced when accounting for the proportion of non-Norwegians.
conclusionBD is a rare disease in Oslo, Norway, with female predominance in Norwegian descendants, but higher prevalence overall in non-Norwegians. The observed increases in incidence and prevalence are likely due to changes in population genetics and introduction of the more sensitive ICBD criteria. Diagnostic delays are common, a significant concern, in Behçet's disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.